Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Retained Earnings: 2016-2025

Historic Retained Earnings for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$1.4 billion.

  • Rocket Pharmaceuticals' Retained Earnings fell 20.69% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 20.69%. This contributed to the annual value of -$1.2 billion for FY2024, which is 26.97% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Retained Earnings stood at -$1.4 billion, which was down 3.70% from -$1.4 billion recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Retained Earnings registered a high of -$363.0 million during Q1 2021, and its lowest value of -$1.4 billion during Q3 2025.
  • Over the past 3 years, Rocket Pharmaceuticals' median Retained Earnings value was -$1.1 billion (recorded in 2024), while the average stood at -$1.1 billion.
  • Data for Rocket Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 74.69% (in 2021) over the last 5 years.
  • Rocket Pharmaceuticals' Retained Earnings (Quarterly) stood at -$491.9 million in 2021, then tumbled by 45.10% to -$713.8 million in 2022, then slumped by 34.41% to -$959.4 million in 2023, then declined by 26.97% to -$1.2 billion in 2024, then decreased by 20.69% to -$1.4 billion in 2025.
  • Its Retained Earnings was -$1.4 billion in Q3 2025, compared to -$1.4 billion in Q2 2025 and -$1.3 billion in Q1 2025.